Sprycel Dose Reduction To Be Considered By Oncology Cmte. During ASCO Road Show

FDA’s Oncologic Drugs Advisory Committee will review Bristol-Myers Squibb’s data package for the Gleevec-resistant leukemia therapy dasatinib on June 2.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet